MANÜ Telehealth introduces its GLP-1 service through a domestic-pharmacy promise: medication delivered directly from a US 503A pharmacy. Its terms clarify that the platform itself does not practice medicine, and its website says it does not dispense the medication. Those distinctions help identify which organization should answer a clinical, pharmacy or billing question.
This October 15, 2026 review covers MANÜ’s homepage, compounded tirzepatide listing and terms of service. We assessed public descriptions without submitting an application, purchasing medication or testing care. Provider-hosted images and testimonials are not our patient evidence. The separate CoreAge promotion on this publication is a disclosed commercial placement.
The advertised US connection is pharmacy dispensing
MANÜ’s homepage says prescriptions are filled and shipped by licensed US pharmacies and refers specifically to 503A dispensing. Its disclaimer says MANÜ is not an internet pharmacy and does not dispense, ship or distribute medication from its own facility. Read the domestic claim at that stated level.
The reviewed pages do not establish the origin of every active ingredient or name the pharmacy assigned to an individual prescription. Our US-origin guide explains why those are separate questions. Ask for the actual dispensing pharmacy and label information, then verify the relevant pharmacy record instead of treating the platform’s location as a substitute.
The platform and clinical practice have separate roles
The terms of service, dated June 4, 2026, identify MANÜ as a service connecting patients with independent licensed professionals. They state that those professionals make diagnosis and prescribing decisions and that treatment is not guaranteed. The contact section identifies Ziggy Telehealth LLC.
The homepage process describes an assessment, provider review, pharmacy shipment if prescribed and ongoing support. This is a service description rather than an observed consultation. Obtain the clinician’s identity and follow-up contact for the individual plan. A platform can coordinate access while a different organization carries responsibility for the medical decision.
Two daily headlines do not make one reliable quote
The homepage includes GLP-1 starting figures of both $4 per day and $5 per day in different sections. Its FAQ directs readers to product pages and the application for pricing, and says packages include consultation, medication, supplies and shipping. The reviewed tirzepatide page does not settle the exact upfront charge or renewal schedule.
We have not multiplied either headline into a confirmed monthly price. A daily equivalent can hide a longer prepaid term, and a starting rate may apply to a different medication. Request the selected product, total payment, supply length and recurring charge date. That complete quote is the appropriate record for comparing the offer.
The compound’s advertised results need their own evidence
The tirzepatide page describes superior weight-loss results and attributes an up-to-20-percent claim to clinical studies of compounded tirzepatide. We did not identify a linked study of the exact MANÜ preparation establishing that claim. The same page acknowledges that compounded medicines are not FDA-approved.
FDA’s current GLP-1 information explains the regulatory distinction and concerns with unapproved products. A description of tirzepatide’s receptor activity does not establish equivalent performance for every formulation. Our product-form guide offers related questions about matching the evidence to the actual medicine. We do not use MANÜ’s marketing percentage as an expected patient result.
Subscription cancellation does not promise a partial refund
The general subscription terms allow cancellation by contacting MANÜ and say it takes effect at the end of the current billing cycle unless otherwise specified. They generally exclude partial-period refunds and describe limits once services have been rendered or medication dispensed. They separately address orders the company cancels.
The document also contains a nutrition-store section with its own fulfillment and cancellation rules. Those store rules should not automatically be imported into a GLP-1 prescription agreement. Retain the terms accepted for the actual service and clarify the processing cutoff. We did not test cancellation, refunds or support response times.
Coverage and follow-up still depend on the individual plan
The homepage FAQ advertises provider and pharmacy coverage across all 50 states but says coverage can change and will be confirmed through intake. It describes ongoing medical-team support without establishing a guaranteed response deadline in the reviewed text. The terms likewise condition access on authorized service locations.
MANÜ’s public documents support a description of a telehealth and US-pharmacy pathway, with unresolved details about the selected price, assigned professionals and exact-product evidence. The BioPivot review provides another example of separating pharmacy location from approval and fee terms. Use those distinctions alongside the provider directory to compare documented services without assuming that domestic dispensing proves clinical superiority.
Sources and review method
Public documents checked 2026-10-15. Provider pages support attributed service and price descriptions; FDA material supplies regulatory context. We did not conduct a purchase, patient study or professional credential audit. Offers may change.